Immunogenicitet Der udvikledes infliximab- antistoffer hos 38% af patienterne, som fik 3 mg/ kg sammenlignet med 12% af patienterne, som fik 6 mg/ kg.
Immunogenicity Antibodies to infliximab developed in 38% of patients receiving 3 mg/ kg compared with 12% of patients receiving 6 mg/ kg.